Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) will look for acquisitions. Joseph Ciaffoni, Chief Executive Officer said "Our business development strategy is to diversify the organization in one or more of the following ways: diversifying within pain through commercial stage high-synergy acquisitions, diversifying beyond pain through commercial stage lower-synergy acquisitions, and diversifying into non-opioid pain solutions through the acquisition of late-stage development assets defined as Phase II or later that have the potential to generate revenue in the 2025 to 2027 time frame".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.42 USD | +1.63% | +4.54% | +18.32% |
Apr. 11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
Feb. 26 | Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.32% | 1.17B | |
+26.24% | 653B | |
+27.00% | 556B | |
-6.70% | 354B | |
+20.51% | 331B | |
+2.34% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.19% | 144B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical to Seek Acquisitions